ICYMI: Here is your guide to the key regulatory decisions made by the FDA in March 2024, including the data that supported the approvals and expert insights on what they could mean for clinical practice. U.S. FDA #lcsm #leusm #lymsm #blcsm #gyncsm onclive.com/view/march-app…

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024. U.S. FDA #lcsm #leusm #lymsm #blcsm #gyncsm onclive.com/view/march-app…

BREAKING: U.S. FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC #blcsm #oncology onclive.com/view/fda-appro…

We are ten days to the 2024 Philly Bladder Cancer Walk! Please join me and #TeamFoxChase Fox Chase Cancer Center Fox Chase Cancer Center Department of Urology supporting Bladder Cancer Advocacy Network on Sat May 27!!!

secure2.convio.net/bcani/site/TR/…

#WalkToEndBladderCancer #blcsm

.U.S. FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer ascopost.com/news/april-202… #blcsm #bladdercancer #oncology FDA Oncology

Serial testing of ctDNA could have greater clinical utility as a risk stratification tool vs landmark ctDNA testing in patients with high-risk MIBC following cystectomy. Tom Powles Barts Health European Association of Urology (EAU) #EAU24 #blcsm onclive.com/view/serial-ct…

Experts discuss updated findings from key clinical trials presented during the 2024 ASCO Genitourinary Cancers Symposium. Elizabeth Plimack MD Neeraj Agarwal, MD, FASCO Matt Milowsky #blcsm #oncology onclive.com/view/immunothe…

FDA green lights Anktiva + BCG for adults with BCG-unresponsive NMIBC with CIS w/wo papillary tumors. bit.ly/4aSU2JK #BLCSM

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
Paul Viscuse, MD UVA Cancer Center #oncology #MedTwitter #blcsm
onclive.com/view/applying-…

Serial testing of ctDNA could improve risk stratification for determining adjuvant treatment in patients with high-risk muscle-invasive bladder cancer. Tom Powles Barts Health European Association of Urology (EAU) #EAU24 #blcsm onclive.com/view/serial-ct…

The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer. #blcsm #oncology onclive.com/view/nadofarag…

We are ten days to the 2024 Philly Bladder Cancer Walk! Please join me and #TeamFoxChase Fox Chase Cancer Center Fox Chase Cancer Center Department of Urology supporting Bladder Cancer Advocacy Network on Sat May 17

secure2.convio.net/bcani/site/TR/…

#WalkToEndBladderCancer #blcsm

#Clinicaltrial EA8192 aims to find out if treatment with durvalumab and chemotherapy can improve outcomes for patients with high grade upper tract #urothelialcancer prior to nephroureterectomy. bit.ly/ea8192-trial #blcsm #bladdercancer cc: Jean Hoffman-Censits, Petros Grivas

Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder carcinoma. #blcsm | U.S. FDA FDA Oncology

cancernetwork.com/view/fda-appro…

Experts highlight clinical trial updates in muscle-invasive bladder cancer, frontline treatment options in metastatic urothelial carcinoma, and more. Elizabeth Plimack MD Neeraj Agarwal, MD, FASCO Matt Milowsky #blcsm #oncology onclive.com/view/immunothe…

Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive bladder cancer. Vikram M. Narayan, MD Winship Cancer Institute of Emory University #blcsm onclive.com/view/narayan-d…

The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer. #blcsm #oncology onclive.com/view/nadofarag…

Dr. Karine Tawagi highlights several studies in bladder cancer being presented at #AUA24 . Karine Tawagi MD #blcsm #urology #urologist

Watch now: urologytimes.com/view/2024-aua-…

#ICYMI : The FDA has accepted an IND application for UGN-103 to inititate a phase 3 study of the mitomycin-based formulation in patients with low-grade intermediate-risk NMIBC. #blcsm #urology

Read more: urologytimes.com/view/fda-accep…

Immunotherapy-Based Approaches Make Waves in Bladder Cancer Elizabeth Plimack MD Neeraj Agarwal, MD, FASCO Matt Milowsky #blcsm #oncology onclive.com/view/immunothe…